FDA MedWatch - Cubicin (daptomycin): Drug Safety Communication - Risk of Eosinophilic Pneumonia - Drugs.com MedNews
Links shared publicly online about this topic.
- 985total visits
FDA MedWatch - Cubicin (daptomycin): Drug Safety Communication - Risk of Eosinophilic Pneumonia - Drugs.com MedNews
ROCKVILLE, Md., July 29, 2010-ISSUE FDA notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia during treatmen
View full resource at drugs.com
Tags: Pneumonia, Drug, Healthcare, FDA
Most Recently Shared on July 30, 2010 at 11:39 am By:
FDA MedWatch - Cubicin (daptomycin): Drug Safety Communication - Risk of Eosinophilic Pneumonia: ROCKVILLE, Md., J... http://bit.ly/b9uuaB
Advertisement
